TuHURA Biosciences, Inc.

https://www.tuhurabio.com

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company dedicated to developing novel technologies and therapeutics aimed at overcoming primary and acquired resistance to existing cancer immunotherapies. Headquartered in Tampa, Florida, the company focuses on addressing the common reasons why cancer immunotherapies may fail or cease to be effective in many patients. [5, 6, 8, 12, 13, 14, 15, 16, 19]

The company's pipeline includes three distinct technological platforms. Its lead product candidate, IFx-2.0, is an innate immune agonist currently in a Phase 3 registration trial for advanced or metastatic Merkel Cell Carcinoma, designed to overcome primary resistance to checkpoint inhibitors. Additionally, TuHURA Biosciences is developing TBS-2025, a VISTA inhibiting monoclonal antibody acquired through its merger with Kineta Inc., which is progressing into Phase 1b/2 development for mutNPM1 r/r Acute Myeloid Leukemia (AML). The company also leverages its Delta Opioid Receptor (DOR) technology to create first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) and antibody peptide conjugates (PDCs) that target Myeloid Derived Suppressor Cells (MDSCs) to mitigate immune-suppressing effects within the tumor microenvironment. [5, 6, 9, 12, 13, 14, 15, 16, 17, 18]

Recent developments include the announcement of a $50 million credit facility and royalty transaction in April 2026, extending its anticipated cash runway into 2028. TuHURA Biosciences also recently appointed Amanda Garofalo as Senior Vice President of Clinical Operations and announced that Dr. Craig Tendler will lead its VISTA program. The company regained compliance with Nasdaq's minimum bid price requirement in February 2026 and filed an Investigational New Drug Application for TBS-2025. Dr. James Bianco serves as the President and Chief Executive Officer. [2, 3, 4, 9, 14, 21]

Latest updates

TuHURA Secures $50 Million Credit Facility, Royalty Deal from Key Investor

Event summary

  • TuHURA Biosciences secured a $50 million credit facility from an affiliate of its largest shareholder, K&V Investment One LLC.
  • The facility carries a 12% annual interest rate and matures in April 2031, with monthly drawdowns.
  • In exchange for the credit facility, TuHURA granted the lender a low to mid-single digit royalty on annual sales of IFx-2.0.
  • The funding is intended to support pipeline development, including Phase 3 results for IFx-2.0 and advancement of TBS-2025.

The big picture

This financing structure, involving a large shareholder affiliate as lender and a royalty stake, is atypical for a company nearing Phase 3 trials, suggesting a high degree of confidence in IFx-2.0's potential. It circumvents traditional equity financing, potentially preserving dilution, but introduces a significant financial obligation tied to commercial success. The deal highlights the challenges faced by immuno-oncology companies in securing funding given the high failure rate in later-stage clinical development.

What we're watching

Financial Health
The company's ability to manage the 12% interest rate on the credit facility will be critical to maintaining financial stability, especially if IFx-2.0 Phase 3 results are delayed or unfavorable.
Shareholder Influence
The significant financial support from K&V Investment One LLC suggests a high degree of influence over TuHURA's strategic direction, which could impact decisions regarding pipeline prioritization and potential partnerships.
Regulatory Risk
The timing and outcome of the IFx-2.0 Phase 3 trial will heavily influence the company's ability to draw down the full credit facility and determine the long-term value of the royalty agreement.

TuHURA Adds Seasoned Clinical Ops Exec Amidst Key Trial Milestones

Event summary

  • TuHURA Biosciences appointed Amanda Garofalo as Senior Vice President of Clinical Operations, effective immediately.
  • Garofalo brings over 20 years of experience in Phase I-IV drug and biologic development.
  • She previously held leadership roles at Parabilis Medicines, EMD Serono, Arcus Biosciences, Indivior, Medimmune, and GlaxoSmithKline Pharmaceuticals.
  • Garofalo will work closely with Dr. Craig Tendler and oversee clinical operations for IFx-2.0 (Phase 3), TBS-2025 (Phase 1b/2), and early-stage ADCs.

The big picture

TuHURA’s appointment of a seasoned clinical operations executive signals a focus on accelerating its pipeline, particularly as it approaches a critical Phase 3 trial for IFx-2.0. The company's acquisition of Kineta and TBS-2025 adds complexity to its portfolio, requiring strong operational leadership to manage diverse programs. This hire suggests TuHURA is proactively addressing the challenges of scaling clinical operations to support multiple development programs and potential regulatory submissions.

What we're watching

Execution Risk
Garofalo's experience will be critical as TuHURA navigates the accelerated approval pathway for IFx-2.0 and the complexities of advancing TBS-2025 into Phase 1b/2.
Clinical Trial Enrollment
Given Garofalo’s prior experience, how effectively she can optimize enrollment rates across TuHURA’s trials will be a key indicator of progress.
ADC Development
The company’s plans for ADC development are nascent; the speed at which these programs advance will reflect the integration of Garofalo’s expertise and the allocation of resources.

TuHURA Bolsters Pipeline, Burns Cash in 2025

Event summary

  • TuHURA Biosciences reported $20.5 million in R&D expenses for 2025, up from $13.3 million in 2024, with pro forma expenses including Kineta at $22.1 million.
  • The company raised $21.2 million through registered direct offerings and private placements in 2025, ending the year with $3.6 million in cash.
  • TuHURA acquired rights to VISTA inhibiting antibody TBS-2025 from Kineta for $10.5 million.
  • Enrollment for the Phase 3 IFx-2.0 trial in Merkel Cell Carcinoma is now anticipated to be completed in mid-2027.
  • TuHURA appointed Craig Tendler, M.D. as a strategic advisor to oversee clinical development, effectively acting as a Chief Medical Officer.

The big picture

TuHURA's strategy of acquiring promising assets like TBS-2025 reflects a common approach in immuno-oncology – leveraging existing pipelines to accelerate development. However, the company’s substantial cash burn and reliance on capital markets highlight the financial pressures facing smaller biopharma companies pursuing complex clinical trials. The appointment of a de facto CMO suggests a focus on streamlining clinical operations, but the delayed enrollment timeline indicates potential challenges ahead.

What we're watching

Cash Runway
With a significant cash burn and limited near-term revenue, TuHURA’s ability to secure additional funding will be critical to sustaining its development programs, particularly as the Phase 3 trial progresses.
Clinical Execution
The delayed enrollment timeline for the Phase 3 trial raises questions about operational efficiency and potential setbacks in achieving accelerated approval for IFx-2.0.
Pipeline Diversification
The success of the ADC program, and its ability to generate data and attract investment, will be key to diversifying TuHURA’s pipeline beyond its reliance on IFx-2.0 and TBS-2025.

TuHURA Taps J&J Oncology Vet to Drive VISTA Program

Event summary

  • Craig Tendler, M.D., former Global Head of Oncology Clinical Development at Johnson & Johnson, will serve as TuHURA Biosciences’ de facto Chief Medical Officer (CMO) and remain on the Board of Directors.
  • Tendler brings a track record of over 30 oncology regulatory approvals and significant experience with hematologic malignancies, including J&J’s menin inhibitor, bleximenib.
  • He will focus on TuHURA’s VISTA inhibiting antibody, TBS-2025, for acute myeloid leukemia (AML), particularly in the NPM1 mutated subset.
  • TuHURA acquired TBS-2025 in June 2025 through its merger with Kineta Inc.
  • Preliminary FDA feedback has been received regarding the early development plan for TBS-2025.

The big picture

The appointment of a seasoned executive like Tendler signals TuHURA’s commitment to advancing its VISTA program, a critical area in immuno-oncology where resistance remains a significant hurdle. Tendler’s experience with J&J, particularly his involvement in the approval of blockbuster hematologic drugs and the development of bleximenib, provides TuHURA with valuable expertise as it seeks to capitalize on the growing market for targeted AML therapies. This move suggests a strategic focus on accelerating clinical trials and securing regulatory approvals for TBS-2025.

What we're watching

Clinical Execution
The success of TBS-2025 hinges on Tendler’s ability to navigate the regulatory pathway and accelerate clinical development, particularly given the complexity of AML and the need for combination therapies.
FDA Engagement
How closely TuHURA can collaborate with the FDA, building on initial feedback, will dictate the speed and efficiency of TBS-2025’s advancement.
Competitive Landscape
The emergence of other VISTA inhibitors and menin inhibitors will likely intensify competition and pressure TuHURA to demonstrate a differentiated clinical profile for TBS-2025.

TuHURA Biosciences Regains Nasdaq Compliance After Price Dip

Event summary

  • TuHURA Biosciences (HURA) received confirmation from Nasdaq that it has regained compliance with the $1.00 minimum bid price requirement.
  • The compliance was achieved after 11 consecutive trading days (Feb 10 - Feb 25, 2026) where the stock price remained above $1.00.
  • The Nasdaq delisting issue stemmed from a prior period of price decline, a common risk for smaller biotech companies.
  • TuHURA is currently in Phase 3 clinical trials for IFX-2.0 in Merkel Cell Carcinoma, combined with Keytruda.
  • TBS-2025, acquired through the Kineta merger in June 2025, is advancing to Phase 2 trials for relapsed/refractory AML.

The big picture

TuHURA's regaining Nasdaq compliance is a temporary reprieve, highlighting the precarious position many smaller, clinical-stage biotech companies face. The company's valuation remains heavily dependent on the success of its lead asset, IFX-2.0, and the ongoing financial pressures inherent in drug development. The Kineta merger added TBS-2025 to the pipeline, but also brought on additional financial obligations and integration challenges.

What we're watching

Clinical Progress
The success of the Phase 3 trial for IFX-2.0 will be critical in sustaining the current stock price and avoiding future delisting concerns; a failure could trigger renewed downward pressure.
Financial Runway
Given the ongoing clinical trials and development programs, TuHURA’s cash runway will need to be carefully monitored to ensure continued operations and avoid the need for dilutive financing.
Pipeline Expansion
The company’s ability to advance its antibody-drug conjugate and antibody-peptide conjugate programs beyond preclinical stages will be a key indicator of long-term value creation and diversification beyond IFX-2.0 and TBS-2025.

TuHURA to Pitch Investors as Phase 3 Trial Looms

Event summary

  • TuHURA Biosciences CEO James Bianco will present at the Citizens Life Science Conference on March 10, 2026.
  • Bianco will also be available for one-on-one investor meetings at the Leerink Global Healthcare Conference on March 11, 2026.
  • TuHURA is currently conducting a Phase 3 trial of IFx-2.0 in combination with Keytruda for Merkel Cell Carcinoma.
  • The company acquired TBS-2025 through a merger with Kineta Inc. on June 30, 2025.
  • TBS-2025 is in Phase 2 development for acute myeloid leukemia (AML).

The big picture

TuHURA's investor conference appearances highlight the critical juncture the company faces as it progresses its lead asset, IFx-2.0, through a Phase 3 trial. The company's strategy of targeting immunotherapy resistance, a significant unmet need in oncology, positions it within a competitive landscape. The acquisition of TBS-2025 expands the pipeline, but also introduces integration and development risks that investors will scrutinize.

What we're watching

Clinical Execution
The success of the upcoming Phase 3 trial for IFx-2.0 will be the primary driver of investor sentiment, and any setbacks could significantly impact valuation.
Pipeline Diversification
How effectively TuHURA integrates and advances TBS-2025 through Phase 2 development will demonstrate the value of the Kineta merger.
Market Adoption
The pace at which physicians adopt IFx-2.0, assuming positive trial results, will determine its commercial viability against established checkpoint inhibitors.

TuHURA Advances TBS-2025 into Phase 2 AML Trial with VISTA Inhibition

Event summary

  • TuHURA Biosciences filed an Investigational New Drug (IND) application with the FDA for TBS-2025, a VISTA-inhibiting antibody.
  • The Phase 2 trial will evaluate TBS-2025 in combination with a menin inhibitor for mutNPM1 relapsed/refractory Acute Myeloid Leukemia (AML).
  • TBS-2025 was acquired by TuHURA through a merger with Kineta Inc. on June 30, 2025.
  • The Phase 2 trial is expected to initiate in early Q2 2026, with preliminary Stage 1 results anticipated in Q3 2026.
  • Current menin inhibitor therapies for mutNPM1 r/r AML have CR/CRh rates below 25% and short duration.

The big picture

The development of TBS-2025 addresses a significant unmet need in the treatment of relapsed/refractory AML, a disease with poor prognosis and limited therapeutic options. The acquisition of TBS-2025 by TuHURA expands its immuno-oncology pipeline and leverages the company’s expertise in overcoming resistance to cancer immunotherapy. The reliance on a menin inhibitor as a combination partner introduces a dependency on the continued success and market penetration of that class of drugs.

What we're watching

Clinical Efficacy
The success of the Phase 2 trial hinges on whether the combination of TBS-2025 and a menin inhibitor significantly improves response rates and duration compared to existing therapies, which currently have limited efficacy.
Regulatory Pathway
TuHURA's stated intention to pursue accelerated approval will depend heavily on the Phase 2 data and FDA’s assessment of the unmet medical need in this patient population.
Competitive Landscape
The emergence of other VISTA inhibitors or novel AML therapies could diminish TBS-2025’s potential market share and necessitate a differentiated clinical profile for success.

TuHURA to Present Key Phase 3 Data at Oppenheimer Conference

Event summary

  • TuHURA Biosciences CEO James Bianco will present at the Oppenheimer Healthcare Life Sciences Conference on February 26, 2026.
  • The presentation will be webcast live and archived on TuHURA's investor relations website.
  • TuHURA's lead candidate, IFx-2.0, is in Phase 3 development as an adjunctive therapy to Keytruda for Merkel Cell Carcinoma.
  • TuHURA acquired TBS-2025 through a merger with Kineta Inc. on June 30, 2025, and it is entering Phase 2 development.

The big picture

TuHURA’s focus on overcoming immunotherapy resistance addresses a significant unmet need in oncology, where a substantial portion of patients experience treatment failure. The Phase 3 trial for IFx-2.0 represents a pivotal moment for the company, as positive results could significantly expand the market for checkpoint inhibitors. The acquisition of TBS-2025 demonstrates a strategic effort to broaden its pipeline and address different cancer types.

What we're watching

Clinical Outcomes
The presentation will likely focus on early data from the Phase 3 trial of IFx-2.0; the success of this trial is critical to TuHURA’s valuation and future pipeline development.
Pipeline Expansion
The company’s progress in leveraging Delta Opioid Receptor technology for bi-specific antibody drug conjugates will be a key indicator of its long-term innovation strategy and potential for diversifying beyond IFx-2.0.
Competitive Landscape
How TuHURA differentiates its approach to overcoming immunotherapy resistance, particularly against established players like Merck (Keytruda), will influence its ability to capture market share.

TuHURA Biosciences Secures Orphan Drug Designation for Melanoma Treatment

Event summary

  • TuHURA Biosciences received Orphan Drug Designation (ODD) from the FDA for its IFx-2.0 therapy targeting stage IIB to stage IV cutaneous melanoma.
  • The ODD is based on Phase 1 trial data published in Molecular Therapeutics, demonstrating clinical benefit in patients refractory to anti-PD1 checkpoint inhibitors.
  • The ODD grants TuHURA seven years of market exclusivity and other benefits including tax credits and FDA assistance.
  • TuHURA is currently enrolling patients in a Phase 3 trial of IFx-2.0 in combination with Keytruda for Merkel Cell Carcinoma.

The big picture

The ODD designation validates TuHURA's approach to overcoming immunotherapy resistance, a significant unmet need in oncology. While the market for melanoma treatments is competitive, IFx-2.0's ability to improve outcomes in patients failing existing therapies positions it as a potentially valuable asset. The company's broader pipeline, including TBS-2025, adds complexity but also diversification to its long-term prospects.

What we're watching

Clinical Trial
The success of the Phase 3 trial in combination with Keytruda will be critical for IFx-2.0's commercial viability and TuHURA's valuation, given the competitive landscape in Merkel Cell Carcinoma.
Regulatory Pathway
How the FDA leverages the ODD designation to expedite review and potential approval of IFx-2.0 for melanoma will influence investor sentiment and future development timelines.
Pipeline Expansion
The company's progress in leveraging Delta Opioid Receptor technology for additional therapies targeting the tumor microenvironment will determine the long-term diversification of TuHURA's pipeline beyond IFx-2.0.

TuHURA Releases Kintara CVRs, Diluting Shareholder Base

Event summary

  • TuHURA Biosciences released 1,539,958 shares of common stock to legacy Kintara Therapeutics stockholders as a result of meeting a contractual safety milestone for REM-001.
  • The milestone was triggered by REM-001’s demonstration of safety and signs of clinical efficacy in a trial of ten metastatic cutaneous breast cancer patients.
  • The release is tied to a Contingent Value Rights Agreement (CVR) dated October 18, 2024.
  • Distribution of the shares is expected to occur within the next ten business days.

The big picture

The release of the Kintara CVRs represents the final resolution of a deal structured to incentivize Kintara’s acquisition. While the milestone achievement is positive, it also introduces immediate dilution for existing TuHURA shareholders. The REM-001 data, while preliminary, highlights the ongoing focus on overcoming immunotherapy resistance, a critical unmet need in oncology, but also carries the risk of over-optimism given the small sample size.

What we're watching

Shareholder Impact
The release of these shares will dilute existing TuHURA shareholders, potentially impacting the stock price and earnings per share. The market's reaction will reflect the perceived value of the released shares relative to the overall company valuation.
REM-001 Efficacy
While the trial met the safety endpoint, the 'signs of clinical efficacy' require further scrutiny. Subsequent data releases will be critical to assess the true therapeutic potential of REM-001 and its impact on TuHURA's pipeline.
Integration Risk
The merger with Kineta and subsequent acquisition of TBS-2025 introduce integration risks. How effectively TuHURA leverages these assets and manages the combined portfolio will influence long-term value creation.
CID: 534